COTA, Inc. Forms Strategic Real-World Data Research Partnership with the Clinical Research Data Sharing Alliance

COTA, Inc. is now a proud member of the Clinical Research Data Sharing Alliance (CRDSA). This cross-industry alliance is dedicated to accelerating the discovery and delivery of life-saving therapies through the use of high-quality clinical trials and real-world data.
What Makes a Fit-for-Purpose Database for Clinical Oncology Research?

A fit-for-purpose database includes key variables, reliable and accurate data, and representative samples that can be used to draw meaningful conclusions. RWD can be highly valuable in supporting clinical oncology research, but choosing the right data is essential. The keys to finding the right fit-for-purpose database include relevance, reliability, integrity, and bias.
COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation

New financing will help COTA expand RWD platform & services to drive more efficient and inclusive drug development.
Early Detection Saves Lives: A Real World Breast Cancer Story

When it comes to cancer, there are a lot of myths and misconceptions out there. But the one thing is for certain: cancer can affect anyone, at any time, and from any background. Hear from one of our own about their battle with breast cancer and how early detection helped them defeat cancer.
Real-World Evidence is Now a “True End-to-End Capability” for Life Science Companies, Says Deloitte

Deloitte’s new Real-World Evidence Survey reveals that life sciences companies are now using real-world data (RWD) and real-world evidence (RWE) throughout the product life cycle—from early discovery through commercialization.
With Tailored, Fit-for-Purpose RWD from COTA, Life Science Companies Can Drive Innovation

Innovation is the key to success in the life sciences industry. But with the vast amounts of data being generated by clinical trials and other research, it can be difficult to know where to focus your efforts. COTA’s tailored, fit-for-purpose real-world data (RWD) can help.
Envisioning the Future of Regulation for Artificial Intelligence in Healthcare

As artificial intelligence revolutionizes healthcare, we must develop a regulatory framework to ensure ethical use of patient data for research and care delivery. But, what should those guardrails look like, and how will we deploy them across the life sciences and clinical care industries? Miruna Sasu shares her thoughts on AI in healthcare and its efficacy with patient data.
COTA Research Showcased High Concordance Rate Between Real-World Physician Response Assessment & the 2017 European LeukemiaNet (ELN) Criteria for Acute Myeloid Leukemia at EHA2022

COTA researchers and collaborators’s recent abstract in the European Hematology Association’s library, found that overall agreement between response categories was 65.1% among AML data.
New Findings Released – RWE Pilot 2.0 Project

Friends of Cancer Research leads collaborative effort including COTA and nine other organizations to advance the collective understanding in applications of real-world data. New findings reveal further insights in non-small cell lung cancer (NSCLC) with a particular focus on novel treatment strategies.
Improving Patients’ Experiences and Outcomes with Technology and Real-World Data

Leading the data and digital team at Novartis, Bruno Villetelle believes that real world data should have a real world impact on patient care. He joins the #RealWorldTalk podcast to discuss how technology and data collection are being used at all stages of treatment to improve patients’ experiences and outcomes.